StockMacro
Menu

Arcus Biosciences

$15.62 -35% in 6 monthsMarket cap $2.2B

RCUS on XNYS, Health Care, Arcus Biosciences, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue fell 65% to $9M in the quarter and losses reached $453M over 12 months.

  • BadFree cash flow negative $466M over 12 months; cash on hand $630M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Industry
Pharmaceutical preparations (Health Care)
Employees
601
Website
arcusbio.com
Listed
NYSE, US
Last results
4 Nov 2026
Next results
expected around 24 Feb 2027 (an estimate: a year ago it reported on 25 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $9.0M, net loss $128.0M.
Quarter to 31 Dec 2021: revenue $354.5M, net income $279.4MQuarter to 31 Dec 2021: revenue $354.5M, net income $279.4MQuarter to 31 Mar 2022: revenue $18.0M, net income -$68.0MQuarter to 31 Mar 2022: revenue $18.0M, net income -$68.0MQuarter to 30 Jun 2022: revenue $26.8M, net income -$66.6MQuarter to 30 Jun 2022: revenue $26.8M, net income -$66.6MQuarter to 30 Sep 2022: revenue $33.6M, net income -$64.9MQuarter to 30 Sep 2022: revenue $33.6M, net income -$64.9MQuarter to 31 Dec 2022: revenue –, net income -$67.5MQuarter to 31 Mar 2023: revenue $25.0M, net income -$80.0MQuarter to 31 Mar 2023: revenue $25.0M, net income -$80.0MQuarter to 30 Jun 2023: revenue $29.0M, net income -$75.0MQuarter to 30 Jun 2023: revenue $29.0M, net income -$75.0MQuarter to 30 Sep 2023: revenue $32.0M, net income -$71.0MQuarter to 30 Sep 2023: revenue $32.0M, net income -$71.0MQuarter to 31 Dec 2023: revenue $31.0M, net income -$81.0MQuarter to 31 Dec 2023: revenue $31.0M, net income -$81.0MQuarter to 31 Mar 2024: revenue $145.0M, net income -$4.0MQuarter to 31 Mar 2024: revenue $145.0M, net income -$4.0MQuarter to 30 Jun 2024: revenue $39.0M, net income -$93.0MQuarter to 30 Jun 2024: revenue $39.0M, net income -$93.0MQuarter to 30 Sep 2024: revenue $48.0M, net income -$92.0MQuarter to 30 Sep 2024: revenue $48.0M, net income -$92.0MQuarter to 31 Dec 2024: revenue $26.0M, net income -$94.0MQuarter to 31 Dec 2024: revenue $26.0M, net income -$94.0MQuarter to 31 Mar 2025: revenue $28.0M, net income -$112.0MQuarter to 31 Mar 2025: revenue $28.0M, net income -$112.0MQuarter to 30 Jun 2025: revenue $160.0M, net income $0Quarter to 30 Jun 2025: revenue $160.0M, net income $0Quarter to 30 Sep 2025: revenue $26.0M, net income -$135.0MQuarter to 30 Sep 2025: revenue $26.0M, net income -$135.0MQuarter to 31 Dec 2025: revenue $33.0M, net income -$106.0MQuarter to 31 Dec 2025: revenue $33.0M, net income -$106.0MQuarter to 31 Mar 2026: revenue $17.0M, net income -$128.0MQuarter to 31 Mar 2026: revenue $17.0M, net income -$128.0MQuarter to 30 Jun 2026: revenue $41.0M, net income -$91.0MQuarter to 30 Jun 2026: revenue $41.0M, net income -$91.0MQuarter to 30 Sep 2026: revenue $9.0M, net income -$128.0MQuarter to 30 Sep 2026: revenue $9.0M, net income -$128.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $354.5M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$9.0M-$128.0M
30 Jun 2026$41.0M-$91.0M
31 Mar 2026$17.0M-$128.0M
31 Dec 2025$33.0M-$106.0M
30 Sep 2025$26.0M-$135.0M
30 Jun 2025$160.0M$0
31 Mar 2025$28.0M-$112.0M
31 Dec 2024$26.0M-$94.0M
30 Sep 2024$48.0M-$92.0M
30 Jun 2024$39.0M-$93.0M
31 Mar 2024$145.0M-$4.0M
31 Dec 2023$31.0M-$81.0M
30 Sep 2023$32.0M-$71.0M
30 Jun 2023$29.0M-$75.0M
31 Mar 2023$25.0M-$80.0M
31 Dec 2022–-$67.5M
30 Sep 2022$33.6M-$64.9M
30 Jun 2022$26.8M-$66.6M
31 Mar 2022$18.0M-$68.0M
31 Dec 2021$354.5M$279.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $100.0M $240.0M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -58% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$453.0M -$341.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$3.64 -$3.44
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -475% -156% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -453% -142% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -114% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$466.0M –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $630.0M $831.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $102.0M $98.0M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$528.0M (net cash) -$733.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.28 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.49
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 22.5 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 17.2 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 6.3 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Arcus BiosciencesRCUS (this company) $2.2Bloss22.5-58%-453%
PerrigoPRGO $2.2Bloss0.54-4.5%-43.3%
NewAmsterdam PharmaNAMS $2.2Bloss85.1-26%-790%
Prestige Consumer HealthcarePBH $2.4B15.22.0+5.1%13.3%
Palvella TherapeuticsPVLA $2.1Bloss–––
MBX BiosciencesMBX $2.5Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$85K

bought $0, sold $85K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+6.6%

243 13F filers vs 228

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

87%

124.9M shares held by 13F filers (30 Sep 2026) of 144.0M outstanding (29 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

9.2%

13.2M shares sold short (30 Oct 2026) of 144.0M outstanding (29 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.6

13.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+6.6%

12.4M shares sold short in the report before, 13.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

43%

43% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 60%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-29%

10 vs 14 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-65%

$9.0M vs $26.0M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

18

18 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

18×

18 articles in the last 7 days; its usual week has 1.

Price $15.62 on 20 Nov 2026, -26% over 12 months (12-month range $15.62 to $31.57)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $9.3M in the last 12 months (the 12 months before: $10.2M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 10 published in the last 12 months, -29% on the 12 months before.
Revenue per quarter. Revenue $9.0M in the latest quarter, -65% on a year earlier.
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 243 13F filers reported holding it in the latest 13F quarter, +33% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
6 Aug 2026Sharp changeQuarterly revenue change: quarterly revenue change, 33.0M vs usual 8.0M (2026-06-30); 4.1x the same period a year earlier
23 Mar 20268-K and other filingsDirector or officer change
23 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Aug 2025Sharp changeQuarterly revenue change: quarterly revenue change, 8.0M vs usual 31.5M (2025-06-30); 0.2x the same period a year earlier
17 Jun 2025Sharp changeShort interest spike: short interest spike, 11.5M vs usual 7.2M (2025-05-30); 1.5x the same period a year earlier
1 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, -181.0M vs usual 32.8M (2024-12-31); -5.8x the same period a year earlier
29 Apr 2025Sharp changeShort interest spike: short interest spike, 9.6M vs usual 6.9M (2025-04-15); 1.4x the same period a year earlier
28 Feb 2025Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 15.4M)
6 Feb 20258-K and other filingsDirector or officer change
21 Jan 20258-K and other filingsDirector or officer change
21 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Nov 2024Sharp changeQuarterly revenue change: quarterly revenue change, 48.0M vs usual 30.0M (2024-09-30); 1.5x the same period a year earlier
30 Jan 20248-K and other filingsDirector or officer change
30 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Mar 20238-K and other filingsDirector or officer change
10 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Nov 2022Sharp changeQuarterly revenue change: quarterly revenue change, 33.6M vs usual 13.7M (2022-09-30); 3.5x the same period a year earlier
9 Aug 2022Sharp changeQuarterly revenue change: quarterly revenue change, 26.8M vs usual 9.5M (2022-06-30); 2.8x the same period a year earlier
1 Mar 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 8.5M vs usual 1.3M (2021-12-31); 5.6x the same period a year earlier
1 Mar 2022Sharp changeQuarterly revenue change: quarterly revenue change, 354.5M vs usual 9.5M (2021-12-31); 37.4x the same period a year earlier
Insider net buying (open market)
Month from 1 Dec 2021: -$2.3M published
Month from 1 Mar 2022: -$304K published
Month from 1 Jun 2022: -$629K published
Month from 1 Sep 2022: -$333K published
Month from 1 Dec 2022: -$1.2M published
Month from 1 Jan 2023: -$45K published
Month from 1 Mar 2023: -$147K published
Month from 1 Jun 2023: -$562K published
Month from 1 Jul 2023: $19.4M published
Month from 1 Aug 2023: -$911K published
Month from 1 Sep 2023: -$427K published
Month from 1 Dec 2023: -$386K published
Month from 1 Jan 2024: -$180K published
Month from 1 Feb 2024: $318.3M published
Month from 1 Mar 2024: -$444K published
Month from 1 Aug 2024: -$20K published
Month from 1 Dec 2024: -$3K published
Month from 1 Jan 2025: -$54K published
Month from 1 Feb 2025: $15.4M published
Month from 1 Sep 2025: -$19K published
Month from 1 Oct 2025: -$2.9M published
Month from 1 Nov 2025: -$2.2M published
Month from 1 Dec 2025: -$5.2M published
Month from 1 Jan 2026: -$835K published
Month from 1 May 2026: -$199K published
Month from 1 Jun 2026: -$944K published
Month from 1 Jul 2026: -$2.0M published
Month from 1 Aug 2026: -$85K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 1 published
Quarter from 1 Apr 2022: 5 published
Quarter from 1 Jul 2022: 9 published
Quarter from 1 Oct 2022: 5 published
Quarter from 1 Jan 2023: 5 published
Quarter from 1 Apr 2023: 3 published
Quarter from 1 Jul 2023: 5 published
Quarter from 1 Oct 2023: 4 published
Quarter from 1 Jan 2024: 1 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2024: 10 published
Quarter from 1 Oct 2024: 3 published
Quarter from 1 Jan 2025: 2 published
Quarter from 1 Apr 2025: 2 published
Quarter from 1 Jul 2025: 8 published
Quarter from 1 Oct 2025: 2 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Jul 2026: 6 published
Quarter from 1 Oct 2026: 2 published
Revenue per quarter
Quarter ended 31 Dec 2021: $354.5M, +3637% on a year earlier; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $18.0M, +90% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $26.8M, +183% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $33.6M, +255% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Mar 2023: $25.0M, +39% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $29.0M, +8.4% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $32.0M, -4.7% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $31.0M; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $145.0M, +480% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $39.0M, +34% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $48.0M, +50% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $26.0M, -16% on a year earlier; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $28.0M, -81% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $160.0M, +310% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $26.0M, -46% on a year earlier; public on 29 Oct 2025
Quarter ended 31 Dec 2025: $33.0M, +27% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $17.0M, -39% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $41.0M, -74% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $9.0M, -65% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $8.5M, +460% on a year earlier; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $2.8M, -23% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $1.5M, -75% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $1.3M, -83% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Mar 2023: $3.0M, +7.6% on a year earlier; public on 10 May 2023
Quarter ended 31 Dec 2023: $6.0M; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $4.0M, +33% on a year earlier; public on 9 May 2024
Quarter ended 30 Sep 2024: $1.0M; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $1.0M, -83% on a year earlier; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $1.0M, -75% on a year earlier; public on 7 May 2025
Quarter ended 31 Dec 2025: $1.0M, 0% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $0; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $0; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 136; public on 14 Feb 2022
31 Mar 2022 report: 150; public on 16 May 2022
30 Jun 2022 report: 165; public on 15 Aug 2022
30 Sep 2022 report: 169; public on 14 Nov 2022
31 Dec 2022 report: 182; public on 14 Feb 2023
31 Mar 2023 report: 170; public on 15 May 2023
30 Jun 2023 report: 166; public on 14 Aug 2023
30 Sep 2023 report: 171; public on 14 Nov 2023
31 Dec 2023 report: 175; public on 14 Feb 2024
31 Mar 2024 report: 164; public on 15 May 2024
30 Jun 2024 report: 181; public on 14 Aug 2024
30 Sep 2024 report: 178; public on 14 Nov 2024
31 Dec 2024 report: 183; public on 14 Feb 2025
31 Mar 2025 report: 179; public on 15 May 2025
30 Jun 2025 report: 174; public on 14 Aug 2025
30 Sep 2025 report: 183; public on 14 Nov 2025
31 Dec 2025 report: 200; public on 17 Feb 2026
31 Mar 2026 report: 207; public on 15 May 2026
30 Jun 2026 report: 228; public on 14 Aug 2026
30 Sep 2026 report: 243; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 243 (30 Sep 2026), 1.4× its normal reading; higher than 100% of its own history.
  • Quarterly revenue change: reported revenue of $33.0M for the quarter ended 30 Jun 2026, 4.1× the same quarter last year Public on 6 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $9.3M in the last 12 months (the 12 months before: $10.2M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 10 published in the last 12 months, -29% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

No trades in the last 90 days; the latest was filed 24 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
24 Aug 2026Alexander AzoyChief Accounting OfficerSellplanned in advance (10b5-1); after exercising options2,827$30.00$85KForm 4
13 Jul 2026Juan C. JaenPresidentSellplanned in advance (10b5-1)68,569$29.63$2.0MForm 4
24 Jun 2026Juan C. JaenPresidentSellplanned in advance (10b5-1)31,431$27.92$878KForm 4
1 Jun 2026Alexander AzoyChief Accounting OfficerSellplanned in advance (10b5-1)2,562$25.77$66KForm 4
12 May 2026Robert C. Goeltz IIChief Financial OfficerSellplanned in advance (10b5-1)7,763$25.63$199KForm 4
7 Jan 2026Juan C. JaenPresidentSellplanned in advance (10b5-1)31,823$21.41$681KForm 4
2 Jan 2026Robert C. Goeltz IIChief Financial OfficerSellplanned in advance (10b5-1)6,552$23.38$153KForm 4
18 Dec 2025Alexander AzoyChief Accounting OfficerSellplanned in advance (10b5-1)8,832$22.13$195KForm 4

243 institutions reported shares at the end of Q3 2026, 87% of the shares outstanding; 44 opened a position, 27 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Gilead Sciences, Inc.31.4M21.8%$811.7MNo change
BlackRock, Inc.16.8M11.7%$434.6M+408K+2.5%
Wellington Management Group LLP6.2M4.28%$159.4M+274K+4.6%
State Street Corp5.6M3.87%$143.9M-459K-7.6%
Vanguard Portfolio Management LLC4.4M3.08%$114.7M-35K-0.8%
FMR LLC (Fidelity)4.4M3.08%$114.6M+387K+9.6%
Vanguard Capital Management LLC3.9M2.73%$101.5M+43K+1.1%
Citadel Advisors LLC3.0M2.06%$76.5M-175K-5.6%
Woodline Partners LP2.9M1.98%$73.7M-153K-5.1%
Janus Henderson Group Ltd.2.5M1.76%$65.6M

Company events

All 35 company events

In 12 months: 1 major agreement, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
23 Mar 2026Director or officer change8-K
18 Dec 2025Signed a major agreementSame filing: took on new debt8-K
6 Feb 2025Director or officer change8-K
21 Jan 2025Director or officer change8-K
27 Aug 2024Signed a major agreementSame filing: took on new debt8-K
30 Jan 2024Director or officer change; Signed a major agreementSame filing: sold shares privately8-K
28 Jun 2023Signed a major agreementSame filing: sold shares privately8-K
15 May 2023Signed a major agreement8-K

The 5 newest of 146 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

1 May 2025confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Arcus Biosciences (RCUS): had 9.6M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year, while it reported revenue of -$181.0M for the quarter ended 31 Dec 2024, 684% below the same quarter last year. Two unrelated kinds of activity within 2 days.

  • Short interest and volume: Short interest spike, became public on 26 Apr 2025
  • Financials: Quarterly revenue change, became public on 1 May 2025
2024-04-15: 6.8M2024-04-30: 7.7M2024-05-15: 7.5M2024-05-31: 7.4M2024-06-14: 7.9M2024-06-28: 6.2M2024-07-15: 6.6M2024-07-31: 6.6M2024-08-15: 7.0M2024-08-30: 6.7M2024-09-13: 6.9M2024-09-30: 6.6M2024-10-15: 6.3M2024-10-31: 6.7M2024-11-15: 7.6M2024-11-29: 8.0M2024-12-13: 7.4M2024-12-31: 7.8M2025-01-15: 8.2M2025-01-31: 6.4M2025-02-14: 6.5M2025-02-28: 6.9M2025-03-14: 7.4M2025-03-31: 8.4M2025-04-15: 9.6M
The 15 Apr 2025 report against the 24 reports before it. this reportearliernormal: 6.9M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 26 Apr 2025

Arcus Biosciences had 9.6M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.

This period
9.6M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
6.9M
Typical spread (median absolute deviation)
486K
How far from its usual level
+3.8
Same report last year
6.8M
History used
2,527 days
2024-04-15: 6.8M2024-04-30: 7.7M2024-05-15: 7.5M2024-05-31: 7.4M2024-06-14: 7.9M2024-06-28: 6.2M2024-07-15: 6.6M2024-07-31: 6.6M2024-08-15: 7.0M2024-08-30: 6.7M2024-09-13: 6.9M2024-09-30: 6.6M2024-10-15: 6.3M2024-10-31: 6.7M2024-11-15: 7.6M2024-11-29: 8.0M2024-12-13: 7.4M2024-12-31: 7.8M2025-01-15: 8.2M2025-01-31: 6.4M2025-02-14: 6.5M2025-02-28: 6.9M2025-03-14: 7.4M2025-03-31: 8.4M2025-04-15: 9.6M
the 15 Apr 2025 report24 earlier reportsnormal: 6.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 1 May 2025

Arcus Biosciences reported revenue of -$181.0M for the quarter ended 31 Dec 2024, 684% below the same quarter last year.

This period
-$181.0M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$32.8M
Typical spread (median absolute deviation)
$5.0M
How far from its usual level
-28.8
Same quarter last year
$31.0M
History used
2,649 days
2022-12-31: $33.7M2023-03-31: $25.0M2023-06-30: $29.0M2023-09-30: $32.0M2023-12-31: $31.0M2024-03-31: $145.0M2024-06-30: $39.0M2024-09-30: $48.0M2024-12-31: $0
the quarter ended 31 Dec 20248 earlier quartersnormal: $32.8M

Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

10 Nov 2020confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Arcus Biosciences (RCUS): had 6.5M shares sold short in the 30 Sep 2020 report, 3.6× the same report last year, while it reported revenue of $64.5M for the quarter ended 30 Sep 2020, 37× the same quarter last year. Two unrelated kinds of activity within 49 days.

  • Short interest and volume: Short interest spike, became public on 10 Oct 2020
  • Short interest and volume: Short interest spike, became public on 27 Oct 2020
  • Financials: Quarterly revenue change, became public on 10 Nov 2020
  • Short interest and volume: Short interest spike, became public on 11 Nov 2020
  • Short interest and volume: Short interest spike, became public on 25 Nov 2020
2019-09-30: 1.8M2019-10-15: 2.0M2019-10-31: 1.6M2019-11-15: 1.6M2019-11-29: 1.4M2019-12-13: 1.5M2019-12-31: 1.4M2020-01-15: 1.4M2020-01-31: 1.3M2020-02-14: 1.2M2020-02-28: 1.5M2020-03-13: 948K2020-03-31: 730K2020-04-15: 673K2020-04-30: 332K2020-05-15: 425K2020-05-29: 1.5M2020-06-15: 1.7M2020-06-30: 3.4M2020-07-15: 4.1M2020-07-31: 4.5M2020-08-14: 5.0M2020-08-31: 5.2M2020-09-15: 5.4M2020-09-30: 6.5M
The 30 Sep 2020 report against the 24 reports before it. this reportearliernormal: 1.5M
See the evidence (5 changes)

Short interest and volume: Short interest spike became public on 10 Oct 2020

Arcus Biosciences had 6.5M shares sold short in the 30 Sep 2020 report, 3.6× the same report last year.

This period
6.5M (the 30 Sep 2020 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
388K
How far from its usual level
+8.6
Same report last year
1.8M
History used
869 days
2019-09-30: 1.8M2019-10-15: 2.0M2019-10-31: 1.6M2019-11-15: 1.6M2019-11-29: 1.4M2019-12-13: 1.5M2019-12-31: 1.4M2020-01-15: 1.4M2020-01-31: 1.3M2020-02-14: 1.2M2020-02-28: 1.5M2020-03-13: 948K2020-03-31: 730K2020-04-15: 673K2020-04-30: 332K2020-05-15: 425K2020-05-29: 1.5M2020-06-15: 1.7M2020-06-30: 3.4M2020-07-15: 4.1M2020-07-31: 4.5M2020-08-14: 5.0M2020-08-31: 5.2M2020-09-15: 5.4M2020-09-30: 6.5M
the 30 Sep 2020 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Oct 2020

Arcus Biosciences had 7.0M shares sold short in the 15 Oct 2020 report, 3.5× the same report last year.

This period
7.0M (the 15 Oct 2020 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
531K
How far from its usual level
+7.0
Same report last year
2.0M
History used
884 days
2019-10-15: 2.0M2019-10-31: 1.6M2019-11-15: 1.6M2019-11-29: 1.4M2019-12-13: 1.5M2019-12-31: 1.4M2020-01-15: 1.4M2020-01-31: 1.3M2020-02-14: 1.2M2020-02-28: 1.5M2020-03-13: 948K2020-03-31: 730K2020-04-15: 673K2020-04-30: 332K2020-05-15: 425K2020-05-29: 1.5M2020-06-15: 1.7M2020-06-30: 3.4M2020-07-15: 4.1M2020-07-31: 4.5M2020-08-14: 5.0M2020-08-31: 5.2M2020-09-15: 5.4M2020-09-30: 6.5M2020-10-15: 7.0M
the 15 Oct 2020 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 10 Nov 2020

Arcus Biosciences reported revenue of $64.5M for the quarter ended 30 Sep 2020, 37× the same quarter last year.

This period
$64.5M (the quarter ended 30 Sep 2020)
Normal quarter (median of 8 earlier)
$1.8M
Typical spread (median absolute deviation)
$0
How far from its usual level
+62.8
Same quarter last year
$1.8M
History used
1,096 days
2018-09-30: $4.3M2018-12-31: $1.6M2019-03-31: $1.8M2019-06-30: $1.8M2019-09-30: $1.8M2019-12-31: $9.8M2020-03-31: $1.8M2020-06-30: $1.8M2020-09-30: $64.5M
the quarter ended 30 Sep 20208 earlier quartersnormal: $1.8M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 11 Nov 2020

Arcus Biosciences had 6.8M shares sold short in the 30 Oct 2020 report, 4.3× the same report last year.

This period
6.8M (the 30 Oct 2020 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
685K
How far from its usual level
+5.2
Same report last year
1.6M
History used
899 days
2019-10-31: 1.6M2019-11-15: 1.6M2019-11-29: 1.4M2019-12-13: 1.5M2019-12-31: 1.4M2020-01-15: 1.4M2020-01-31: 1.3M2020-02-14: 1.2M2020-02-28: 1.5M2020-03-13: 948K2020-03-31: 730K2020-04-15: 673K2020-04-30: 332K2020-05-15: 425K2020-05-29: 1.5M2020-06-15: 1.7M2020-06-30: 3.4M2020-07-15: 4.1M2020-07-31: 4.5M2020-08-14: 5.0M2020-08-31: 5.2M2020-09-15: 5.4M2020-09-30: 6.5M2020-10-15: 7.0M2020-10-30: 6.8M
the 30 Oct 2020 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Nov 2020

Arcus Biosciences had 6.6M shares sold short in the 13 Nov 2020 report, 4.2× the same report last year.

This period
6.6M (the 13 Nov 2020 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
823K
How far from its usual level
+4.2
Same report last year
1.6M
History used
913 days
2019-11-15: 1.6M2019-11-29: 1.4M2019-12-13: 1.5M2019-12-31: 1.4M2020-01-15: 1.4M2020-01-31: 1.3M2020-02-14: 1.2M2020-02-28: 1.5M2020-03-13: 948K2020-03-31: 730K2020-04-15: 673K2020-04-30: 332K2020-05-15: 425K2020-05-29: 1.5M2020-06-15: 1.7M2020-06-30: 3.4M2020-07-15: 4.1M2020-07-31: 4.5M2020-08-14: 5.0M2020-08-31: 5.2M2020-09-15: 5.4M2020-09-30: 6.5M2020-10-15: 7.0M2020-10-30: 6.8M2020-11-13: 6.6M
the 13 Nov 2020 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 6 Aug 2026Financials change

    reported revenue of $33.0M for the quarter ended 30 Jun 2026, 4.1× the same quarter last year.

    Same quarter last year: $8.0M; its normal quarter is $8.0M.

    See the evidence
    This period
    $33.0M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $8.0M
    Typical spread (median absolute deviation)
    $2.5M
    How far from its usual level
    +6.7
    Same quarter last year
    $8.0M
    History used
    3,195 days
    2024-06-30: $39.0M2024-09-30: $48.0M2024-12-31: $02025-03-31: $8.0M2025-06-30: $8.0M2025-09-30: $6.0M2025-12-31: $11.0M2026-03-31: $7.0M2026-06-30: $33.0M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $8.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 23 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 23 Mar 2026Filings record

    Director or officer change

  4. 12 Aug 2025Financials change

    reported revenue of $8.0M for the quarter ended 30 Jun 2025, 79% below the same quarter last year.

    Same quarter last year: $39.0M; its normal quarter is $31.5M.

    See the evidence
    This period
    $8.0M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $31.5M
    Typical spread (median absolute deviation)
    $4.5M
    How far from its usual level
    -3.5
    Same quarter last year
    $39.0M
    History used
    2,830 days
    2022-09-30: $33.6M2023-03-31: $25.0M2023-06-30: $29.0M2023-09-30: $32.0M2023-12-31: $31.0M2024-06-30: $39.0M2024-09-30: $48.0M2025-03-31: $8.0M2025-06-30: $8.0M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $31.5M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  5. 11 Jun 2025Short interest and volume change

    had 11.5M shares sold short in the 30 May 2025 report, 1.5× the same report last year.

    Same report last year: 7.4M; its normal report is 7.2M.

    See the evidence
    This period
    11.5M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    7.2M
    Typical spread (median absolute deviation)
    570K
    How far from its usual level
    +5.1
    Same report last year
    7.4M
    History used
    2,572 days
    2024-05-31: 7.4M2024-06-14: 7.9M2024-06-28: 6.2M2024-07-15: 6.6M2024-07-31: 6.6M2024-08-15: 7.0M2024-08-30: 6.7M2024-09-13: 6.9M2024-09-30: 6.6M2024-10-15: 6.3M2024-10-31: 6.7M2024-11-15: 7.6M2024-11-29: 8.0M2024-12-13: 7.4M2024-12-31: 7.8M2025-01-15: 8.2M2025-01-31: 6.4M2025-02-14: 6.5M2025-02-28: 6.9M2025-03-14: 7.4M2025-03-31: 8.4M2025-04-15: 9.6M2025-04-30: 7.9M2025-05-15: 9.9M2025-05-30: 11.5M
    the 30 May 2025 report24 earlier reportsnormal: 7.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 1 May 2025several at once

    had 9.6M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year, while it reported revenue of -$181.0M for the quarter ended 31 Dec 2024, 684% below the same quarter last year. Two unrelated kinds of activity within 2 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 26 Apr 2025

    Arcus Biosciences had 9.6M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.

    This period
    9.6M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    6.9M
    Typical spread (median absolute deviation)
    486K
    How far from its usual level
    +3.8
    Same report last year
    6.8M
    History used
    2,527 days
    2024-04-15: 6.8M2024-04-30: 7.7M2024-05-15: 7.5M2024-05-31: 7.4M2024-06-14: 7.9M2024-06-28: 6.2M2024-07-15: 6.6M2024-07-31: 6.6M2024-08-15: 7.0M2024-08-30: 6.7M2024-09-13: 6.9M2024-09-30: 6.6M2024-10-15: 6.3M2024-10-31: 6.7M2024-11-15: 7.6M2024-11-29: 8.0M2024-12-13: 7.4M2024-12-31: 7.8M2025-01-15: 8.2M2025-01-31: 6.4M2025-02-14: 6.5M2025-02-28: 6.9M2025-03-14: 7.4M2025-03-31: 8.4M2025-04-15: 9.6M
    the 15 Apr 2025 report24 earlier reportsnormal: 6.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 1 May 2025

    Arcus Biosciences reported revenue of -$181.0M for the quarter ended 31 Dec 2024, 684% below the same quarter last year.

    This period
    -$181.0M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $32.8M
    Typical spread (median absolute deviation)
    $5.0M
    How far from its usual level
    -28.8
    Same quarter last year
    $31.0M
    History used
    2,649 days
    2022-12-31: $33.7M2023-03-31: $25.0M2023-06-30: $29.0M2023-09-30: $32.0M2023-12-31: $31.0M2024-03-31: $145.0M2024-06-30: $39.0M2024-09-30: $48.0M2024-12-31: $0
    the quarter ended 31 Dec 20248 earlier quartersnormal: $32.8M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  7. 1 May 2025Financials change

    reported revenue of -$181.0M for the quarter ended 31 Dec 2024, 684% below the same quarter last year.

    Same quarter last year: $31.0M; its normal quarter is $32.8M.

    See the evidence
    This period
    -$181.0M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $32.8M
    Typical spread (median absolute deviation)
    $5.0M
    How far from its usual level
    -28.8
    Same quarter last year
    $31.0M
    History used
    2,649 days
    2022-12-31: $33.7M2023-03-31: $25.0M2023-06-30: $29.0M2023-09-30: $32.0M2023-12-31: $31.0M2024-03-31: $145.0M2024-06-30: $39.0M2024-09-30: $48.0M2024-12-31: $0
    the quarter ended 31 Dec 20248 earlier quartersnormal: $32.8M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  8. 26 Apr 2025Short interest and volume change

    had 9.6M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.

    Same report last year: 6.8M; its normal report is 6.9M.

    See the evidence
    This period
    9.6M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    6.9M
    Typical spread (median absolute deviation)
    486K
    How far from its usual level
    +3.8
    Same report last year
    6.8M
    History used
    2,527 days
    2024-04-15: 6.8M2024-04-30: 7.7M2024-05-15: 7.5M2024-05-31: 7.4M2024-06-14: 7.9M2024-06-28: 6.2M2024-07-15: 6.6M2024-07-31: 6.6M2024-08-15: 7.0M2024-08-30: 6.7M2024-09-13: 6.9M2024-09-30: 6.6M2024-10-15: 6.3M2024-10-31: 6.7M2024-11-15: 7.6M2024-11-29: 8.0M2024-12-13: 7.4M2024-12-31: 7.8M2025-01-15: 8.2M2025-01-31: 6.4M2025-02-14: 6.5M2025-02-28: 6.9M2025-03-14: 7.4M2025-03-31: 8.4M2025-04-15: 9.6M
    the 15 Apr 2025 report24 earlier reportsnormal: 6.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 28 Feb 2025Insiders change

    had 3 insiders buy $15.4M of its shares on the open market within 30 days (3 filings).

    Who bought: Gilead Sciences, Inc., Rosen Terry J, Kaneko Yasunori.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $15.4M
    Window
    29 Jan 2025 to 28 Feb 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  10. 28 Feb 2025Insiders record

    KANEKO YASUNORI (director) bought 20,000 shares of RCUS ($201,200) (dated 27 Feb 2025)

  11. 28 Feb 2025Insiders record

    ROSEN TERRY J (Chief Executive Officer) bought 19,800 shares of RCUS ($201,564) (dated 27 Feb 2025)

  12. 21 Feb 2025Insiders record

    GILEAD SCIENCES, INC. (ten percent owner) bought 1,363,636 shares of RCUS ($15.0M) (dated 20 Feb 2025)

  13. 6 Feb 2025Filings record

    Director or officer change

  14. 21 Jan 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 21 Jan 2025Filings record

    Director or officer change

  16. 12 Nov 2024Financials change

    reported revenue of $48.0M for the quarter ended 30 Sep 2024, 1.5× the same quarter last year.

    Same quarter last year: $32.0M; its normal quarter is $30.0M.

    See the evidence
    This period
    $48.0M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $30.0M
    Typical spread (median absolute deviation)
    $3.4M
    How far from its usual level
    +3.6
    Same quarter last year
    $32.0M
    History used
    2,557 days
    2022-03-31: $18.0M2022-06-30: $26.8M2022-09-30: $33.6M2023-03-31: $25.0M2023-06-30: $29.0M2023-09-30: $32.0M2023-12-31: $31.0M2024-06-30: $39.0M2024-09-30: $48.0M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $30.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  17. 1 Feb 2024Insiders record

    GILEAD SCIENCES, INC. (ten percent owner) bought 15,238,095 shares of RCUS ($320.0M) (dated 31 Jan 2024)

  18. 30 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 30 Jan 2024Filings record

    Director or officer change

  20. 1 Jul 2023Insiders record

    GILEAD SCIENCES, INC. (ten percent owner) bought 1,010,000 shares of RCUS ($19.5M) (dated 30 Jun 2023)

  21. 10 Mar 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 10 Mar 2023Filings record

    Director or officer change

  23. 8 Nov 2022Financials change

    reported revenue of $33.6M for the quarter ended 30 Sep 2022, 3.5× the same quarter last year.

    Same quarter last year: $9.5M; its normal quarter is $13.7M.

    See the evidence
    This period
    $33.6M (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    $13.7M
    Typical spread (median absolute deviation)
    $4.3M
    How far from its usual level
    +3.1
    Same quarter last year
    $9.5M
    History used
    1,826 days
    2020-09-30: $64.5M2020-12-31: $9.5M2021-03-31: $9.5M2021-06-30: $9.5M2021-09-30: $9.5M2021-12-31: $354.5M2022-03-31: $18.0M2022-06-30: $26.8M2022-09-30: $33.6M
    the quarter ended 30 Sep 20228 earlier quartersnormal: $13.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  24. 9 Aug 2022Financials change

    reported revenue of $26.8M for the quarter ended 30 Jun 2022, 2.8× the same quarter last year.

    Same quarter last year: $9.5M; its normal quarter is $9.5M.

    See the evidence
    This period
    $26.8M (the quarter ended 30 Jun 2022)
    Normal quarter (median of 8 earlier)
    $9.5M
    Typical spread (median absolute deviation)
    $3.9M
    How far from its usual level
    +3.0
    Same quarter last year
    $9.5M
    History used
    1,734 days
    2020-06-30: $1.8M2020-09-30: $64.5M2020-12-31: $9.5M2021-03-31: $9.5M2021-06-30: $9.5M2021-09-30: $9.5M2021-12-31: $354.5M2022-03-31: $18.0M2022-06-30: $26.8M
    the quarter ended 30 Jun 20228 earlier quartersnormal: $9.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  25. 1 Mar 2022Financials change

    reported revenue of $354.5M for the quarter ended 31 Dec 2021, 37× the same quarter last year.

    Same quarter last year: $9.5M; its normal quarter is $9.5M.

    See the evidence
    This period
    $354.5M (the quarter ended 31 Dec 2021)
    Normal quarter (median of 8 earlier)
    $9.5M
    Typical spread (median absolute deviation)
    $158K
    How far from its usual level
    +345.0
    Same quarter last year
    $9.5M
    History used
    1,553 days
    2019-12-31: $9.8M2020-03-31: $1.8M2020-06-30: $1.8M2020-09-30: $64.5M2020-12-31: $9.5M2021-03-31: $9.5M2021-06-30: $9.5M2021-09-30: $9.5M2021-12-31: $354.5M
    the quarter ended 31 Dec 20218 earlier quartersnormal: $9.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  26. 1 Mar 2022Financials change

    spent $8.5M on capital projects in the quarter ended 31 Dec 2021, 5.6× the same quarter last year.

    Same quarter last year: $1.5M; its normal quarter is $1.3M.

    See the evidence
    This period
    $8.5M (the quarter ended 31 Dec 2021)
    Normal quarter (median of 8 earlier)
    $1.3M
    Typical spread (median absolute deviation)
    $1.1M
    How far from its usual level
    +4.5
    Same quarter last year
    $1.5M
    History used
    1,736 days
    2019-12-31: $196K2020-03-31: $209K2020-06-30: $256K2020-09-30: $1.1M2020-12-31: $1.5M2021-03-31: $3.6M2021-06-30: $6.1M2021-09-30: $7.9M2021-12-31: $8.5M
    the quarter ended 31 Dec 20218 earlier quartersnormal: $1.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  27. 9 Nov 2021Financials change

    spent $7.9M on capital projects in the quarter ended 30 Sep 2021, 7.3× the same quarter last year.

    Same quarter last year: $1.1M; its normal quarter is $810K.

    See the evidence
    This period
    $7.9M (the quarter ended 30 Sep 2021)
    Normal quarter (median of 8 earlier)
    $810K
    Typical spread (median absolute deviation)
    $608K
    How far from its usual level
    +7.0
    Same quarter last year
    $1.1M
    History used
    1,644 days
    2019-09-30: $550K2019-12-31: $196K2020-03-31: $209K2020-06-30: $256K2020-09-30: $1.1M2020-12-31: $1.5M2021-03-31: $3.6M2021-06-30: $6.1M2021-09-30: $7.9M
    the quarter ended 30 Sep 20218 earlier quartersnormal: $810K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  28. 11 Aug 2021Filings record

    Director or officer change

  29. 10 Aug 2021Financials change

    spent $6.1M on capital projects in the quarter ended 30 Jun 2021, 24× the same quarter last year.

    Same quarter last year: $256K; its normal quarter is $550K.

    See the evidence
    This period
    $6.1M (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    $550K
    Typical spread (median absolute deviation)
    $348K
    How far from its usual level
    +5.5
    Same quarter last year
    $256K
    History used
    1,552 days
    2019-06-30: $551K2019-09-30: $550K2019-12-31: $196K2020-03-31: $209K2020-06-30: $256K2020-09-30: $1.1M2020-12-31: $1.5M2021-03-31: $3.6M2021-06-30: $6.1M
    the quarter ended 30 Jun 20218 earlier quartersnormal: $550K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  30. 5 Aug 2021Filings record

    Director or officer change

  31. 19 Jul 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 19 Jul 2021Filings record

    Director or officer change

  33. 27 Apr 2021Insiders record

    KANEKO YASUNORI (director) bought 4,133 shares of RCUS ($129,652) (dated 26 Apr 2021)

  34. 16 Apr 2021Filings record

    Delisting notice or listing transfer

  35. 3 Apr 2021Insiders record

    FALBERG KATHRYN E (director) bought 20,000 shares of RCUS ($567,000) (dated 2 Apr 2021)

  36. 3 Feb 2021Insiders record

    GILEAD SCIENCES INC (ten percent owner) bought 5,650,000 shares of RCUS ($220.3M) (dated 2 Feb 2021)

  37. 6 Jan 2021Filings record

    Director or officer change

  38. 18 Dec 2020Filings record

    Director or officer change

  39. 25 Nov 2020Short interest and volume change

    had 6.6M shares sold short in the 13 Nov 2020 report, 4.2× the same report last year.

    Same report last year: 1.6M; its normal report is 1.5M.

    See the evidence
    This period
    6.6M (the 13 Nov 2020 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    823K
    How far from its usual level
    +4.2
    Same report last year
    1.6M
    History used
    913 days
    2019-11-15: 1.6M2019-11-29: 1.4M2019-12-13: 1.5M2019-12-31: 1.4M2020-01-15: 1.4M2020-01-31: 1.3M2020-02-14: 1.2M2020-02-28: 1.5M2020-03-13: 948K2020-03-31: 730K2020-04-15: 673K2020-04-30: 332K2020-05-15: 425K2020-05-29: 1.5M2020-06-15: 1.7M2020-06-30: 3.4M2020-07-15: 4.1M2020-07-31: 4.5M2020-08-14: 5.0M2020-08-31: 5.2M2020-09-15: 5.4M2020-09-30: 6.5M2020-10-15: 7.0M2020-10-30: 6.8M2020-11-13: 6.6M
    the 13 Nov 2020 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 11 Nov 2020Short interest and volume change

    had 6.8M shares sold short in the 30 Oct 2020 report, 4.3× the same report last year.

    Same report last year: 1.6M; its normal report is 1.5M.

    See the evidence
    This period
    6.8M (the 30 Oct 2020 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    685K
    How far from its usual level
    +5.2
    Same report last year
    1.6M
    History used
    899 days
    2019-10-31: 1.6M2019-11-15: 1.6M2019-11-29: 1.4M2019-12-13: 1.5M2019-12-31: 1.4M2020-01-15: 1.4M2020-01-31: 1.3M2020-02-14: 1.2M2020-02-28: 1.5M2020-03-13: 948K2020-03-31: 730K2020-04-15: 673K2020-04-30: 332K2020-05-15: 425K2020-05-29: 1.5M2020-06-15: 1.7M2020-06-30: 3.4M2020-07-15: 4.1M2020-07-31: 4.5M2020-08-14: 5.0M2020-08-31: 5.2M2020-09-15: 5.4M2020-09-30: 6.5M2020-10-15: 7.0M2020-10-30: 6.8M
    the 30 Oct 2020 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 89 entries; narrow the window or the kind of data to see older ones.

Not listed: 182 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001724521
Ticker
RCUS
Domain
arcusbio.com
Employer name
Arcus Biosciences, Inc. (1 unverified)
Hq location
CA|HAYWARD|94545 (1 unverified)
Name
Arcus Biosciences, Inc.
Wikidata
Q113503877
  • DOL H-1B labor condition applications and PERM certifications380 data points27 Jan 2020 to 3 Aug 2026
  • SEC Form 13F institutional holdings315 data points31 Mar 2018 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)136 records16 Feb 2018 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)598 data points31 Dec 2015 to 29 Oct 2026
  • SEC Form 4 insider transactions101 records, 288 data points19 Mar 2018 to 24 Aug 2026
  • FINRA short interest (twice monthly)606 data points15 May 2018 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026